Docetaxel more active than paclitaxel as second-line therapy for metastatic breast cancer

S.E. Jones, J. Erban, B. Overmoyer, G.T. Budd, L. Hutchins, E. Lower, L. Laufman, S. Sundaram, W.J. Urba, K.I. Pritchard, R. Mennel, D. Richards, S. Olsen, M.L. Meyers, P.M. Ravdin. J Clin Oncol 2005;23(24):5542–5551

Aileen L. Chen NYU Medical Center, New York, NY, 10016, USA

Anna Pavlick NYU Cancer Center, New York, NY, 10016, USA

References

Nabholtz JM, Senn HJ, Bezwoda WR, et al. Prospective randomized trial of docetaxel versus mitomycin plus vinblastine in patients with metastatic breast cancer progressing despite previous anthracycline-containing che-motherapy. 304 Study Group. J Clin Oncol 1999;17:1413–1424
PubMed Web of Science ®Google Scholar
Sjostrom J, Blomqvist C, Mourdsen H, et al. Docetaxel compared with sequential methrotrexate and 5-fluorouracil in patients with advanced breast cancer after anthracycline failure: A randomised phase III study with crossover on progression by the Scandinavian Breast Group. Eur J Cancer 1999;35:1194–1201
PubMed Web of Science ®Google Scholar
Bonneterre J, Roche H, Monnier A, et al. Docetaxel VS 5-fluororuacil plus vinorelbine in metastatic breast cancer after anthracycline therapy failure. Br J Cancer 2002;87: 1210–1215
PubMed Web of Science ®Google Scholar
Icli E, Akbulut h, Uner A, et al. Paclitaxel (T) vs cisplatin + VP-16 (EP) in metastatic breast cancer patients treated with anthracyclines: A phase III randomized study. Turkish Oncology Group. Ann Oncol 2002; 13 (supp1.5 ):47
Google Scholar

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Docetaxel more active than paclitaxel as second-line therapy for metastatic breast cancer

S.E. Jones, J. Erban, B. Overmoyer, G.T. Budd, L. Hutchins, E. Lower, L. Laufman, S. Sundaram, W.J. Urba, K.I. Pritchard, R. Mennel, D. Richards, S. Olsen, M.L. Meyers, P.M. Ravdin. J Clin Oncol 2005;23(24):5542–5551

References

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Docetaxel more active than paclitaxel as second-line therapy for metastatic breast cancer

S.E. Jones, J. Erban, B. Overmoyer, G.T. Budd, L. Hutchins, E. Lower, L. Laufman, S. Sundaram, W.J. Urba, K.I. Pritchard, R. Mennel, D. Richards, S. Olsen, M.L. Meyers, P.M. Ravdin. J Clin Oncol 2005;23(24):5542–5551

References

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date